John D. Gordan

9.5k total citations · 4 hit papers
72 papers, 5.9k citations indexed

About

John D. Gordan is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, John D. Gordan has authored 72 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 27 papers in Cancer Research and 21 papers in Oncology. Recurrent topics in John D. Gordan's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer, Hypoxia, and Metabolism (12 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers). John D. Gordan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer, Hypoxia, and Metabolism (12 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers). John D. Gordan collaborates with scholars based in United States, Germany and China. John D. Gordan's co-authors include M. Celeste Simon, J. Alan Diehl, Craig B. Thompson, Cheng‐Jun Hu, Jianping Jin, Sara B. Cullinan, J. Wade Harper, Jessica A. Bertout, Brian Keith and Kelly L. Covello and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

John D. Gordan

68 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Keap1-BTB Protein Is an Adaptor That Bridges Nrf2 to a Cul3-Based E3 Ligase: Oxidative Stress Sensing by a Cul3-Keap1 Ligase

2004 827 citations John D. Gordan, J. Alan Diehl et al. profile →
HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth

2006 657 citations Kelly L. Covello, John D. Gordan et al. Genes & Development profile →
HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and Proliferation

2007 623 citations John D. Gordan, Craig B. Thompson et al. Cancer Cell profile →
HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity

2007 619 citations John D. Gordan, Jessica A. Bertout et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John D. Gordan United States	27	4.0k	2.6k	1.1k	757	694	72	5.9k
M. James You United States	36	4.5k 1.1×	2.5k 1.0×	2.1k 1.9×	979 1.3×	1.1k 1.5×	129	7.3k
Libing Song China	53	5.5k 1.4×	3.4k 1.3×	1.7k 1.5×	693 0.9×	812 1.2×	146	7.3k
Dung‐Fang Lee United States	36	4.9k 1.2×	1.4k 0.5×	1.6k 1.4×	660 0.9×	391 0.6×	87	6.3k
Peggy P. Hsu United States	13	4.2k 1.1×	1.5k 0.6×	758 0.7×	569 0.8×	526 0.8×	19	5.7k
Arnab Chakravarti United States	45	3.2k 0.8×	2.1k 0.8×	1.3k 1.1×	473 0.6×	1.1k 1.5×	173	6.1k
Richard Possemato United States	26	4.1k 1.0×	1.9k 0.7×	832 0.7×	601 0.8×	892 1.3×	40	5.5k
Giovanna Chiorino Italy	37	3.0k 0.8×	1.3k 0.5×	1.3k 1.2×	578 0.8×	532 0.8×	113	4.8k
Gong Yang China	45	2.8k 0.7×	1.5k 0.6×	1.4k 1.3×	625 0.8×	461 0.7×	108	5.0k
Yanhua Zheng United States	27	3.8k 1.0×	2.2k 0.8×	782 0.7×	585 0.8×	276 0.4×	34	5.2k
Daoyan Wei United States	43	4.3k 1.1×	1.7k 0.6×	2.0k 1.8×	632 0.8×	380 0.5×	75	6.2k

Countries citing papers authored by John D. Gordan

Since Specialization

Citations

This map shows the geographic impact of John D. Gordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Gordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Gordan more than expected).

Fields of papers citing papers by John D. Gordan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Gordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Gordan. The network helps show where John D. Gordan may publish in the future.

Co-authorship network of co-authors of John D. Gordan

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Gordan. A scholar is included among the top collaborators of John D. Gordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Gordan. John D. Gordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stevers, Nicholas, Carter J. Barger, Chibo Hong, et al.. (2025). The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible. Molecular Cell. 85(12). 2337–2354.e9. 1 indexed citations

Tischfield, David J., John D. Gordan, Emma E. Furth, et al.. (2024). Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. JHEP Reports. 7(3). 101264–101264.

Rosanna, K., Matt Kanke, John D. Gordan, et al.. (2024). DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. PLoS Genetics. 20(3). e1011216–e1011216. 4 indexed citations

Li, Michael, Lindsay M. Hannan, Lipika Goyal, et al.. (2024). Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma—a real-world, multicenter study. Therapeutic Advances in Medical Oncology. 16. 12741821–12741821. 1 indexed citations

Gordan, John D., et al.. (2023). New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. Drugs. 83(12). 1091–1109. 9 indexed citations

Dinh, Timothy A., Alan F. Utria, Kevin C. Barry, et al.. (2022). A framework for fibrolamellar carcinoma research and clinical trials. Nature Reviews Gastroenterology & Hepatology. 19(5). 328–342. 22 indexed citations

Gordan, John D., et al.. (2021). Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Computational Biology. 17(2). e1008699–e1008699. 6 indexed citations

Wang, Jingxiao, Haichuan Wang, Ning Ding, et al.. (2019). Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. Journal of Hepatology. 71(4). 742–752. 47 indexed citations

Brand, Toni M., et al.. (2018). Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. 38(11). 1936–1950. 25 indexed citations

10.

Donnella, Hayley, James T. Webber, Rebecca S. Levin, et al.. (2018). Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology. 14(8). 768–777. 67 indexed citations

11.

Montesion, Meagan, Thomas Botton, Eric A. Collisson, et al.. (2018). Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. The Oncologist. 23(9). 998–1003. 3 indexed citations

12.

Rajaram, Satwik, John D. Gordan, Agnieszka K. Witkiewicz, et al.. (2017). Sampling strategies to capture single-cell heterogeneity. Nature Methods. 14(10). 967–970. 24 indexed citations

13.

Urisman, Anatoly, Rebecca S. Levin, John D. Gordan, et al.. (2016). An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases. Molecular & Cellular Proteomics. 16(2). 265–277. 31 indexed citations

14.

Sos, Martin L., Rebecca S. Levin, John D. Gordan, et al.. (2014). Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors. Cell Reports. 8(4). 1037–1048. 55 indexed citations

15.

Dondeti, Vijay R., Bradley Wubbenhorst, Priti Lal, et al.. (2011). Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma Define Disease Subtypes and Potential New Therapeutic Targets. Cancer Research. 72(1). 112–121. 43 indexed citations

16.

Bertout, Jessica A., Amar J. Majmundar, John D. Gordan, et al.. (2009). HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proceedings of the National Academy of Sciences. 106(34). 14391–14396. 148 indexed citations

17.

Wright, Tricia M., A. Rose Brannon, John D. Gordan, et al.. (2009). Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 28(27). 2513–2523. 92 indexed citations

18.

Gordan, John D., Jessica A. Bertout, Cheng‐Jun Hu, J. Alan Diehl, & M. Celeste Simon. (2007). HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell. 11(4). 335–347. 619 indexed citations breakdown →

19.

Lum, Julian J., Thi Bui, Michaela Gruber, et al.. (2007). The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes & Development. 21(9). 1037–1049. 337 indexed citations

20.

Wang, Hongyan, Fiona E. McCann, John D. Gordan, et al.. (2004). ADAP–SLP-76 Binding Differentially Regulates Supramolecular Activation Cluster (SMAC) Formation Relative to T Cell–APC Conjugation. The Journal of Experimental Medicine. 200(8). 1063–1074. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact